Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Collegium Pharmaceutical Inc's Business Segments
Collegium Pharmaceutical Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single Reportable
Total Revenue
$ 137
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single Reportable0%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable | $ 194 | - |
Revenue by Product & Service Category - Q1 FY2026
- Belbuca38.4%
- Xtampza ER37%
- Jornay PM28.3%
- Nucynta IR19%
- Nucynta ER13.3%
- Symproic3.1%
- Nucynta ER AG1.1%
- Nucynta IR AG0.9%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Belbuca | $ 53 | 38.4% |
| Xtampza ER | $ 51 | 37% |
| Jornay PM | $ 39 | 28.3% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
5 more categories available
Sign in to unlock the full Collegium Pharmaceutical Inc dataset.
Description of Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc is a publicly traded specialty pharmaceutical company based in Stoughton, Massachusetts. It was founded in 2002 by Michael Heffernan, who is the current CEO, and Joseph Ciaffoni, the current COO.
The company specializes in the development and commercialization of innovative treatments for chronic pain and other conditions. They work to address unmet medical needs by developing new treatments that are safer, more effective, and more accessible than the current standard of care.
One of Collegium's most successful products is Xtampza ER, an extended-release opioid medication for the treatment of chronic pain. Xtampza ER was approved by the FDA in 2016 and is designed to be harder to abuse than other opioids. It is also formulated to be tamper-resistant, which reduces the risk of addiction and overdose.
Collegium also offers an innovative drug delivery technology platform called DETERx. This technology allows medication to be released slowly over time, which helps to reduce the risk of abuse and addiction. DETERx is used in Xtampza ER and other Collegium products.
The company has a strong research and development pipeline, with several products in various stages of development. In addition to chronic pain, they are also exploring treatments for other conditions such as neuropathic pain and opioid use disorder.
Collegium is committed to patient-centered care and works to ensure that their products are safe, effective, and accessible to those who need them. They have a team of experienced professionals and a strong corporate culture that focuses on innovation, collaboration, and excellence.
Overall, Collegium Pharmaceutical Inc is a leading specialty pharmaceutical company that is dedicated to improving the lives of patients with chronic pain and other conditions. Their innovative products and drug delivery technologies are helping to reduce the risk of addiction and overdose, while providing effective relief to those who need it most.
The company specializes in the development and commercialization of innovative treatments for chronic pain and other conditions. They work to address unmet medical needs by developing new treatments that are safer, more effective, and more accessible than the current standard of care.
One of Collegium's most successful products is Xtampza ER, an extended-release opioid medication for the treatment of chronic pain. Xtampza ER was approved by the FDA in 2016 and is designed to be harder to abuse than other opioids. It is also formulated to be tamper-resistant, which reduces the risk of addiction and overdose.
Collegium also offers an innovative drug delivery technology platform called DETERx. This technology allows medication to be released slowly over time, which helps to reduce the risk of abuse and addiction. DETERx is used in Xtampza ER and other Collegium products.
The company has a strong research and development pipeline, with several products in various stages of development. In addition to chronic pain, they are also exploring treatments for other conditions such as neuropathic pain and opioid use disorder.
Collegium is committed to patient-centered care and works to ensure that their products are safe, effective, and accessible to those who need them. They have a team of experienced professionals and a strong corporate culture that focuses on innovation, collaboration, and excellence.
Overall, Collegium Pharmaceutical Inc is a leading specialty pharmaceutical company that is dedicated to improving the lives of patients with chronic pain and other conditions. Their innovative products and drug delivery technologies are helping to reduce the risk of addiction and overdose, while providing effective relief to those who need it most.
Collegium Pharmaceutical Inc. is a dynamic and focused specialty pharmaceutical company that aims to create and advance innovative solutions for patients suffering from chronic pain and its related conditions. With a strong emphasis on the development and commercialization of proprietary, abuse-deterrent medications, Collegium is dedicated to addressing the growing concerns surrounding opioid use and addiction.
Segments:
Collegium Pharmaceutical Inc operates exclusively within the pharmaceutical sector, concentrating on the development of medications specifically designed to manage chronic pain. This single segment focus enables the company to channel its resources, expertise, and research into creating products that effectively address the complex needs of patients experiencing persistent pain.
Products:
Collegiums product portfolio features a range of advanced opioid therapies equipped with abuse-deterrent technologies. Notable products include:
1. Xtampza ER:
- Description: Xtampza ER is an extended-release formulation of oxycodone, tailored to provide consistent pain relief over a 12-hour period. It is designed to be taken two times a day.
- Abuse-Deterrent Properties: The unique formulation and delivery system are specifically designed to deter abuse. When tampered with, Xtampza ER resists manipulation methods commonly used to misuse opioids, thereby reducing the potential for misuse and addiction.
- Indications: Xtampza is primarily indicated for the management of severe pain that requires around-the-clock opioid treatment, especially for patients who are already opioid-tolerant.
2. Nucynta ER:
- Description: Nucynta ER is a strong opioid agonist available in an extended-release formulation. It is indicated for the treatment of severe pain that cannot be adequately managed with non-opioid medications alone.
- Mechanism of Action: As a mu-opioid receptor agonist, Nucynta ER provides effective analgesia while also impacting norepinephrine reuptake, adding an additional pathway for pain relief.
- Abuse Deterrence: Similar to Xtampza, Nucynta ER incorporates features designed to deter abuse, offering an essential option for pain management while minimizing risks associated with significant opioid use.
3. DETERx:
- Description: DETERx is a proprietary technology platform that creates extended-release medications capable of providing effective pain relief while simultaneously deterring abuse.
- Mechanism: This innovative formulation alters the release profile of opioid medications when tampered with, thereby discouraging misuse by providing inconsistent or reduced efficacy in altered states.
- Applications: DETERx technology has the potential to be utilized across a variety of pain management products, further expanding Collegium’s offerings in the chronic pain market.
Services:
Collegium Pharmaceutical Inc. extends beyond product development by offering a suite of services that support the lifecycle of its medications:
1. Research and Development:
- The company is committed to advancing the field of pain management through extensive research initiatives. Collegium invests significantly in R&D, focusing on discovering new treatments and improving existing formulations.
2. Manufacturing:
- Collegiums state-of-the-art manufacturing facilities are designed to uphold the highest standards of quality and safety. They utilize advanced technologies and processes to ensure the integrity and effectiveness of its medications.
3. Commercialization:
- A dedicated commercial team of professionals works on marketing and selling the products directly to healthcare providers, pharmacies, and patients. This team employs targeted strategies to effectively communicate the benefits and unique properties of Collegiums offerings.
4. Distribution:
- Collegium manages an efficient distribution network that ensures timely access to its products. Collaborating with various wholesalers and distributors, the company aims to minimize barriers to availability, allowing healthcare providers and patients to obtain the medications they need without delay.
Summary:
Collegium Pharmaceutical Inc. stands out in the pharmaceutical landscape due to its unwavering commitment to enhancing the lives of patients suffering from chronic pain. Through its focus on innovative, abuse-deterrent technologies and comprehensive services that encompass R&D, manufacturing, commercialization, and distribution, Collegium is well-positioned as a leader in the development of safer opioid medications. With its continual investment in research and development, the company seeks not only to provide effective pain relief but also to play a pivotal role in addressing the opioid crisis through responsible prescribing and usage of its products.
Segments:
Collegium Pharmaceutical Inc operates exclusively within the pharmaceutical sector, concentrating on the development of medications specifically designed to manage chronic pain. This single segment focus enables the company to channel its resources, expertise, and research into creating products that effectively address the complex needs of patients experiencing persistent pain.
Products:
Collegiums product portfolio features a range of advanced opioid therapies equipped with abuse-deterrent technologies. Notable products include:
1. Xtampza ER:
- Description: Xtampza ER is an extended-release formulation of oxycodone, tailored to provide consistent pain relief over a 12-hour period. It is designed to be taken two times a day.
- Abuse-Deterrent Properties: The unique formulation and delivery system are specifically designed to deter abuse. When tampered with, Xtampza ER resists manipulation methods commonly used to misuse opioids, thereby reducing the potential for misuse and addiction.
- Indications: Xtampza is primarily indicated for the management of severe pain that requires around-the-clock opioid treatment, especially for patients who are already opioid-tolerant.
2. Nucynta ER:
- Description: Nucynta ER is a strong opioid agonist available in an extended-release formulation. It is indicated for the treatment of severe pain that cannot be adequately managed with non-opioid medications alone.
- Mechanism of Action: As a mu-opioid receptor agonist, Nucynta ER provides effective analgesia while also impacting norepinephrine reuptake, adding an additional pathway for pain relief.
- Abuse Deterrence: Similar to Xtampza, Nucynta ER incorporates features designed to deter abuse, offering an essential option for pain management while minimizing risks associated with significant opioid use.
3. DETERx:
- Description: DETERx is a proprietary technology platform that creates extended-release medications capable of providing effective pain relief while simultaneously deterring abuse.
- Mechanism: This innovative formulation alters the release profile of opioid medications when tampered with, thereby discouraging misuse by providing inconsistent or reduced efficacy in altered states.
- Applications: DETERx technology has the potential to be utilized across a variety of pain management products, further expanding Collegium’s offerings in the chronic pain market.
Services:
Collegium Pharmaceutical Inc. extends beyond product development by offering a suite of services that support the lifecycle of its medications:
1. Research and Development:
- The company is committed to advancing the field of pain management through extensive research initiatives. Collegium invests significantly in R&D, focusing on discovering new treatments and improving existing formulations.
2. Manufacturing:
- Collegiums state-of-the-art manufacturing facilities are designed to uphold the highest standards of quality and safety. They utilize advanced technologies and processes to ensure the integrity and effectiveness of its medications.
3. Commercialization:
- A dedicated commercial team of professionals works on marketing and selling the products directly to healthcare providers, pharmacies, and patients. This team employs targeted strategies to effectively communicate the benefits and unique properties of Collegiums offerings.
4. Distribution:
- Collegium manages an efficient distribution network that ensures timely access to its products. Collaborating with various wholesalers and distributors, the company aims to minimize barriers to availability, allowing healthcare providers and patients to obtain the medications they need without delay.
Summary:
Collegium Pharmaceutical Inc. stands out in the pharmaceutical landscape due to its unwavering commitment to enhancing the lives of patients suffering from chronic pain. Through its focus on innovative, abuse-deterrent technologies and comprehensive services that encompass R&D, manufacturing, commercialization, and distribution, Collegium is well-positioned as a leader in the development of safer opioid medications. With its continual investment in research and development, the company seeks not only to provide effective pain relief but also to play a pivotal role in addressing the opioid crisis through responsible prescribing and usage of its products.